What Myung In Pharm does

Myung In Pharm (명인제약) is a South Korea-based pharmaceutical manufacturer founded in 1985 and listed on the Korea Exchange (KRX:317450), operating two manufacturing sites in Hwaseong-si, Gyeonggi-do: the Paltan 1st Factory for finished dosage forms and R&D, and the Baran 2nd Factory for API production and pellet formulation. The company historically generated revenue from prescription drugs (e.g., Newpram Odi/escitalopram for depression and bipolar disorder, Myungin Disgren/triflusal for thrombosis) and OTC products (Colgreen A cold remedy, Foxen naproxen analgesic) distributed through Korean pharmaceutical wholesalers to hospitals, clinics, and pharmacies. The firm is executing a strategic transition from an OTC drug maker into a CNS-focused specialty pharmaceutical developer anchored by proprietary pellet formulation technology using a Glatt fluidized bed granulator, with growth platforms in new drug development, licensing, and global CDMO services.

The company's current development pipeline is concentrated in central nervous system therapeutics. Its lead asset, Paxroyah (P2B001), is an improved Parkinson's disease drug combining rasagiline and pramipexole in a sustained-release pellet formulation, for which global IP rights across 15 countries were acquired from Israeli partner Pharma Two B via a Tel Aviv court-supervised asset sale in January 2026 after P2B entered receivership; Korean marketing approval was filed in September 2025 with a 2027 launch target. Myung In Pharm also holds exclusive South Korean development and commercialization rights to Newron Pharmaceuticals' evenamide, a Phase III novel glutamate modulator for treatment-resistant schizophrenia, as part of the ENIGMA-TRS program. Pellet formulation capacity at the Baran 2nd Factory is being expanded to support global contract manufacturing and export of finished pellet products.

The business model combines three revenue streams: domestic pharmaceutical product sales through Korean wholesale distribution (regulated by National Health Insurance pricing), contract development and manufacturing organization (CDMO) services leveraging pellet formulation know-how for international pharma clients, and future drug development/licensing income from Paxroyah and evenamide commercialization and out-licensing. Sales-led go-to-market is executed through traditional Korean pharma channels, with planned international expansion via licensing-out and CMO partnerships. The company is privately/founder-controlled (CEO Lee Hang Myung) and operates with ISO 37001 anti-bribery certification, with English, Japanese, and Korean corporate presence.

Name

Myung In Pharm

Legal name

MYUNG-IN PHARM

Website

https://myunginph.co.kr

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

11–50 employees

Short description

Myung In Pharm is a South Korean pharmaceutical company transitioning from OTC drug manufacturing to CNS specialty drug development, leveraging proprietary pellet formulation technology to develop and commercialize Parkinson's and schizophrenia therapies while expanding global CDMO services.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Prescription pharmaceuticals
• CNS drug development
• Pellet formulation manufacturing
• CDMO services
• OTC pharmaceuticals

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Sale of prescription pharmaceuticals (전문의약품) including CNS drugs like Newpram Odi for depression/bipolar disorder, Myungin Disgren for thrombosis, and OTC products like Colgreen A and Foxen for pain/fever relief. Revenue generated from domestic Korean pharmaceutical distribution.
2. CDMO Services: Contract Development and Manufacturing Organization services. The company is expanding its pellet formulation capacity at the Baran 2nd Factory and plans to produce finished products for global export for CMO business.
3. Drug Development/Licensing: Development and commercialization of new CNS drugs. The company holds development and commercialization agreements with partners like Newron for South Korea, and is pursuing global business expansion through overseas partnerships and licensing-out for products like Paxloxyah.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Myung In Pharm manufactures and markets prescription and OTC pharmaceutical products across CNS, cardiovascular, and general health therapeutic areas. The company's portfolio includes antidepressants (Newpram Odi), antiplatelets (Myungin Disgren), CNS agents (Perkin CR for Parkinson's, Amisul for schizophrenia, Atomoxin for ADHD, Carmazepine CR for epilepsy), and OTC medications (Colgreen A cold remedy, Foxen analgesic). It is transitioning into a CNS-focused new drug developer with Paxroyah (P2B001), a pellet-formulation Parkinson's drug with global IP rights, and licensed rights to evenamide for treatment-resistant schizophrenia in South Korea, while expanding CDMO services and pellet formulation capacity at its Hwaseong manufacturing facilities.

Product overview

Myung In Pharm (명인제약) is a South Korean pharmaceutical company transitioning from an over-the-counter drug manufacturer to a CNS-focused new drug developer. The company manufactures and markets prescription pharmaceuticals and OTC medications across therapeutic areas including CNS (antidepressants, antipsychotics, Parkinson's disease, ADHD, epilepsy), cardiovascular (antiplatelets, thrombosis prevention), and general healthcare (cold medications, gastrointestinal, anti-inflammatory). Key prescription CNS products include 뉴프람오디정 (escitalopram for depression/anxiety), 명인디스그렌캡슐 (triflusal for thrombosis), Amisul Tab. (schizophrenia), Perkin CR Tab. (Parkinson's), Atomoxin Cap. (ADHD), and Carmazepine CR Tab. (epilepsy). The company is developing 팍스로야캡슐 (Parkinson's drug acquired from P2B) and holds South Korean rights to evenamide for treatment-resistant schizophrenia. Myung In Pharm operates two manufacturing facilities in Hwaseong, Gyeonggi Province and offers CDMO services including pellet formulation manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• 이가탄: Product brand for gum disease treatment
• 메이킨
• Paxroyah (팍스로야캡슐)
• 명인다문화장학재단

Products and services

• Newpram Odi Tablet (뉴프람오디정) Prescription antidepressant and anti-anxiety medication containing escitalopram oxalate; oral disintegrating tablets in 5mg, 10mg, and 20mg strengths used to treat major depressive disorder, panic disorder with or without agoraphobia, social anxiety disorder, generalized anxiety disorder, and obsessive-compulsive disorder.
• Myungin Disgren Capsule (명인디스그렌캡슐) Prescription antiplatelet agent containing triflusal, in 150mg and 300mg capsules, indicated for prevention of arterial thromboembolic diseases including acute myocardial infarction due to unstable angina, thrombosis after vascular surgery, and cerebrovascular disorders.
• Colgreen A Capsule (콜그린에이캡슐) OTC comprehensive cold medication containing acetaminophen, etenzamide, caffeine, chlorpheniramine maleate, dextromethorphan hydrobromide, furthiathiazole hydrochloride, riboflavin, and dl-methylephedrine hydrochloride; relieves cold symptoms including nasal congestion, sneezing, sore throat, cough, chills, fever, headache, and muscle pain.
• Foxen Tablet (폭센정) OTC antipyretic, analgesic, and anti-inflammatory medication containing naproxen sodium 275mg; used for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendinitis, acute gout, dysmenorrhea, and pain relief.
• Superpirin Cap. Prescription thrombosis and antiplatelet medication listed in the English-language product catalog.
• Mayqueen Q EC Tab. OTC gastrointestinal medication listed in the English-language product catalog.
• Igatan F Cap. OTC gum disease treatment medication listed in the English-language product catalog.
• Atomoxin Cap. Prescription ADHD (Attention Deficit Hyperactivity Disorder) medication listed in the Japanese-language product catalog.
• Carmazepine CR Tab. Prescription antiepileptic medication (carbamazepine extended-release tablet) listed in the Japanese-language product catalog; used for the treatment of epilepsy.
• Perkin CR Tab. Prescription Parkinson's disease medication listed in the Japanese-language product catalog.
• Amisul Tab. Prescription antipsychotic medication for schizophrenia treatment listed in the Japanese-language product catalog.
• Paxroyah Capsule (팍스로야캡슐) / Paxloxyah (P2B001) In-development Parkinson's disease drug containing rasagiline and pramipexole in a pellet formulation with sustained-release coating, produced using Glatt fluidized bed granulator (FBG) technology. Global IP rights (3 patents in 15 countries, trademarks, trade secrets, clinical trial data) acquired from Israeli partner P2B (Pharma Two B) through Israeli Tel Aviv court-supervised asset sale, with Korean marketing approval filed and a 2027 domestic launch targeted.
• CDMO Services (Contract Development and Manufacturing Organization) Contract development and manufacturing services including pellet formulation production using Glatt FBG technology. The company is expanding pellet formulation capacity at Baran 2nd Factory for finished-product manufacturing and global export as part of its strategic CMO/CDMO business.
• Evenamide (South Korea license) Novel glutamate modulator in-licensed from Newron Pharmaceuticals for development and commercialization in South Korea as a treatment for treatment-resistant schizophrenia, advancing through Phase III clinical trials as add-on therapy to existing antipsychotics including clozapine.

Quantifiable outcome

• More than half of treatment-resistant schizophrenia patients treated with evenamide no longer met severity criteria for TRS after long-term treatment
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Newron PharmaceuticalscoreStrategic or Co-development PartnerDevelopment and commercialization agreement for evenamide (novel glutamate modulator for treatment-resistant schizophrenia) in South Korea. Myung In Pharm holds exclusive rights to develop and commercialize the drug in the Korean market. The partnership is part of Newron's global ENIGMA-TRS Phase III program.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Hanmi Pharmaceutical: Major South Korean pharmaceutical company with a strong CNS and specialty drug pipeline and global licensing-out model; the most direct Korean analogue to Myung In Pharm's CNS-focused, licensing-driven strategy.
• SK Biopharmaceuticals: Korean CNS-focused specialty pharma that developed and globalized cenobamate (Xcopri) for epilepsy; directly comparable as a Korean-listed company commercializing CNS assets through partnerships and licensing.
• Daewoong Pharmaceutical: South Korean pharma with prescription CNS, OTC and CDMO activities and a track record of pellet/extended-release formulation technology; comparable across both CNS pipeline and dosage-form manufacturing.
• Boryung Pharmaceutical: Korean pharma with a portfolio spanning CNS, cardiovascular and OTC products distributed domestically through hospital and pharmacy channels; directly comparable in therapeutic mix and Korean market focus.

Broad incumbents

• Yuhan Corporation: Large established Korean pharmaceutical company with diversified branded Rx, OTC and API businesses; broader incumbent with overlapping CNS, cardiovascular and OTC product lines.
• Dong-A Pharmaceutical: Established Korean pharma with branded prescription and consumer health products; comparable across OTC heritage and CNS/cardiovascular portfolio, though larger and more diversified.
• Recipharm: Global CDMO with expertise in pellet and modified-release oral solid dose manufacturing; representative of the global CDMO competitive set Myung In Pharm is targeting with its Baran 2nd Factory expansion.
• Catalent: Large global CDMO with deep capabilities in oral controlled-release and pellet-based formulations; relevant peer for Myung In Pharm's CDMO ambition and the standard its pellet platform must compete against.

Emerging players

• Newron Pharmaceuticals: European CNS-focused biotech developing evenamide (Phase III ENIGMA-TRS); comparable as the originator of Myung In Pharm's flagship schizophrenia asset and a CNS pure-play.

Regional players

• Celltrion: Korean biopharmaceutical company with strong domestic manufacturing infrastructure and global expansion through licensing; relevant Korean listed-peer for capital-markets and export-driven growth comparisons.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Myung In Pharm